Parkinson’s disease Therapeutics Market, by Product (Dopamine Agonists, Monoamine Oxidase Inhibitors (MAOIs), Catechol-O-methyl transferase (COMT) Inhibitors, Peripheral Decarboxylase Inhibitors, Levodopa combination therapy, Others), Route Of Addministartion (Transdermal, Oral, Subcutaneous, Intestinal Infusion, Others): Global Opportunity Analysis and Industry Forecast, 2020-2027

1. RESEARCH METHODOLOGY

• 1.1. Desk Research

• 1.2. Real time insights and validation

• 1.3. Forecast model

• 1.4. Assumptions and forecast parameters

• 1.5. Market size estimation

  • 1.5.1. Top-down approach

  • 1.5.2. Bottom-up approach

2. REPORT SCOPE

• 2.1. Market definition

• 2.2. Key objectives of the study

• 2.3. Report overview

• 2.4. Market segmentation

• 2.5. Overview of the impact of COVID-19 on Global Parkinson’s disease Therapeutics Market

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

• 4.1. Introduction

• 4.2. Growth impact forces

  • 4.2.1. Drivers

  • 4.2.2. Restraints

  • 4.2.3. Opportunities

• 4.3. Market value chain analysis

  • 4.3.1. List of raw material suppliers

  • 4.3.2. List of manufacturers

  • 4.3.3. List of distributors

• 4.4. Innovation & sustainability matrices

  • 4.4.1. Technology matrix

  • 4.4.2. Regulatory matrix

• 4.5. Porter’s five forces analysis

  • 4.5.1. Bargaining power of suppliers

  • 4.5.2. Bargaining power of consumers

  • 4.5.3. Threat of substitutes

  • 4.5.4. Threat of new entrants

  • 4.5.5. Competitive rivalry intensity

• 4.6. PESTLE analysis

  • 4.6.1. Political

  • 4.6.2. Economical

  • 4.6.3. Social

  • 4.6.4. Technological

  • 4.6.5. Environmental

• 4.7. Impact of COVID-19 on Parkinson’s disease Therapeutics Market

  • 4.7.1. Pre-covid market scenario

  • 4.7.2. Post-covid market scenario

5. Parkinson’s Disease Therapeutics Market, By Technology

• 5.1. Overview

• 5.2 Dopamine Agonists

  • 5.2.1 Definition, key trends, growth factors, and opportunities

  • 5.2.2 Market size analysis, by region, 2020-2027

  • 5.2.3 Market share analysis, by country, 2020-2027

• 5.3 Monoamine Oxidase Inhibitors (MAOIs)

  • 5.3.1 Definition, key trends, growth factors, and opportunities

  • 5.3.2 Market size analysis, by region, 2020-2027

  • 5.3.3 Market share analysis, by country, 2020-2027

• 5.4 Catechol-O-methyl transferase (COMT) Inhibitors

  • 5.4.1 Definition, key trends, growth factors, and opportunities

  • 5.4.2 Market size analysis, by region, 2020-2027

  • 5.4.3 Market share analysis, by country, 2020-2027

• 5.5 Peripheral Decarboxylase Inhibitors

  • 5.5.1 Definition, key trends, growth factors, and opportunities

  • 5.5.2 Market size analysis, by region, 2020-2027

  • 5.5.3 Market share analysis, by country, 2020-2027

• 5.6 Levodopa combination therapy

  • 5.6.1 Definition, key trends, growth factors, and opportunities

  • 5.6.2 Market size analysis, by region, 2020-2027

  • 5.6.3 Market share analysis, by country, 2020-2027

• 5.7 Others

  • 5.7.1 Definition, key trends, growth factors, and opportunities

  • 5.7.2 Market size analysis, by region, 2020-2027

  • 5.7.3 Market share analysis, by country, 2020-2027

• 5.8 Research Dive Exclusive Insights

  • 5.8.1 Market attractiveness

  • 5.8.2 Competition heatmap

6. Parkinson’s Disease Therapeutics Market, By Location

• 6.1. Overview

• 6.2 Transdermal

  • 6.2.1 Definition, key trends, growth factors, and opportunities

  • 6.2.2 Market size analysis, by region, 2020-2027

  • 6.2.3 Market share analysis, by country, 2020-2027

• 6.3 Oral

  • 6.3.1 Definition, key trends, growth factors, and opportunities

  • 6.3.2 Market size analysis, by region, 2020-2027

  • 6.3.3 Market share analysis, by country, 2020-2027

• 6.4 Subcutaneous

  • 6.4.1 Definition, key trends, growth factors, and opportunities

  • 6.4.2 Market size analysis, by region, 2020-2027

  • 6.4.3 Market share analysis, by country, 2020-2027

• 6.5 Intestinal Infusion

  • 6.5.1 Definition, key trends, growth factors, and opportunities

  • 6.5.2 Market size analysis, by region, 2020-2027

  • 6.5.3 Market share analysis, by country, 2020-2027

• 6.6 Others

  • 6.6.1 Definition, key trends, growth factors, and opportunities

  • 6.6.2 Market size analysis, by region, 2020-2027

  • 6.6.3 Market share analysis, by country, 2020-2027

• 6.7 Research Dive Exclusive Insights

  • 6.7.1 Market attractiveness

  • 6.7.2 Competition heatmap

7. Parkinson’s Disease Therapeutics Market, By Region

• 7.1 North America

  • 7.1.1 U.S

    • 7.1.1.1 Market size analysis, By Technology, 2020-2027

    • 7.1.1.2 Market size analysis, By Location, 2020-2027

  • 7.1.2 Canada

    • 7.1.2.1 Market size analysis, By Technology, 2020-2027

    • 7.1.2.2 Market size analysis, By Location, 2020-2027

  • 7.1.3 Mexico

    • 7.1.3.1 Market size analysis, By Technology, 2020-2027

    • 7.1.3.2 Market size analysis, By Location, 2020-2027

  • 7.1.4 Research Dive Exclusive Insights

    • 7.1.4.1 Market attractiveness

    • 7.1.4.2 Competition heatmap

• 7.2 Europe

  • 7.2.1 Germany

    • 7.2.1.1 Market size analysis, By Technology, 2020-2027

    • 7.2.1.2 Market size analysis, By Location, 2020-2027

  • 7.2.2 UK

    • 7.2.2.1 Market size analysis, By Technology, 2020-2027

    • 7.2.2.2 Market size analysis, By Location, 2020-2027

  • 7.2.3 France

    • 7.2.3.1 Market size analysis, By Technology, 2020-2027

    • 7.2.3.2 Market size analysis, By Location, 2020-2027

  • 7.2.4 Spain

    • 7.2.4.1 Market size analysis, By Technology, 2020-2027

    • 7.2.4.2 Market size analysis, By Location, 2020-2027

  • 7.2.5 Italy

    • 7.2.5.1 Market size analysis, By Technology, 2020-2027

    • 7.2.5.2 Market size analysis, By Location, 2020-2027

  • 7.2.6 Rest of Europe

    • 7.2.6.1 Market size analysis, By Technology, 2020-2027

    • 7.2.6.2 Market size analysis, By Location, 2020-2027

  • 7.2.7 Research Dive Exclusive Insights

    • 7.2.7.1 Market attractiveness

    • 7.2.7.2 Competition heatmap

• 7.3 Asia-Pacific

  • 7.3.1 China

    • 7.3.1.1 Market size analysis, By Technology, 2020-2027

    • 7.3.1.2 Market size analysis, By Location, 2020-2027

  • 7.3.2 Japan

    • 7.3.2.1 Market size analysis, By Technology, 2020-2027

    • 7.3.2.2 Market size analysis, By Location, 2020-2027

  • 7.3.3 India

    • 7.3.3.1 Market size analysis, By Technology, 2020-2027

    • 7.3.3.2 Market size analysis, By Location, 2020-2027

  • 7.3.4 Australia

    • 7.3.4.1 Market size analysis, By Technology, 2020-2027

    • 7.3.4.2 Market size analysis, By Location, 2020-2027

  • 7.3.5 South Korea

    • 7.3.5.1 Market size analysis, By Technology, 2020-2027

    • 7.3.5.2 Market size analysis, By Location, 2020-2027

  • 7.3.6 Rest of Asia-Pacific

    • 7.3.6.1 Market size analysis, By Technology, 2020-2027

    • 7.3.6.2 Market size analysis, By Location, 2020-2027

  • 7.3.7 Research Dive Exclusive Insights

    • 7.3.7.1 Market attractiveness

    • 7.3.7.2 Competition heatmap

• 7.4 LAMEA

  • 7.4.1 Brazil

    • 7.4.1.1 Market size analysis, By Technology, 2020-2027

    • 7.4.1.2 Market size analysis, By Location, 2020-2027

  • 7.4.2 Saudi Arabia

    • 7.4.2.1 Market size analysis, By Technology, 2020-2027

    • 7.4.2.2 Market size analysis, By Location, 2020-2027

  • 7.4.3 UAE

    • 7.4.3.1 Market size analysis, By Technology, 2020-2027

    • 7.4.3.2 Market size analysis, By Location, 2020-2027

  • 7.4.4 South Africa

    • 7.4.4.1 Market size analysis, By Technology, 2020-2027

    • 7.4.4.2 Market size analysis, By Location, 2020-2027

  • 7.4.5 Rest of LAMEA

    • 7.4.5.1 Market size analysis, By Technology, 2020-2027

    • 7.4.5.2 Market size analysis, By Location, 2020-2027

  • 7.4.6 Research Dive Exclusive Insights

    • 7.4.6.1 Market attractiveness

    • 7.4.6.2 Competition heatmap

8. Competitive Landscape

• 8.1 Top winning strategies, 2020-2027

  • 8.1.1 By strategy

  • 8.1.2 By year

• 8.2 Strategic overview

• 8.3 Market share analysis, 2020-2027

9. Company Profiles

• 9.1 Teva

  • 9.1.1 Overview

  • 9.1.2 Business segments

  • 9.1.3 Product portfolio

  • 9.1.4 Financial performance

  • 9.1.5 Recent developments

  • 9.1.6 SWOT analysis

• 9.2 Novartis AG

  • 9.2.1 Overview

  • 9.2.2 Business segments

  • 9.2.3 Product portfolio

  • 9.2.4 Financial performance

  • 9.2.5 Recent developments

  • 9.2.6 SWOT analysis

• 9.3 GSK

  • 9.3.1 Overview

  • 9.3.2 Business segments

  • 9.3.3 Product portfolio

  • 9.3.4 Financial performance

  • 9.3.5 Recent developments

  • 9.3.6 SWOT analysis

• 9.4 AbbVie

  • 9.4.1 Overview

  • 9.4.2 Business segments

  • 9.4.3 Product portfolio

  • 9.4.4 Financial performance

  • 9.4.5 Recent developments

  • 9.4.6 SWOT analysis

• 9.5 Merck

  • 9.5.1 Overview

  • 9.5.2 Business segments

  • 9.5.3 Product portfolio

  • 9.5.4 Financial performance

  • 9.5.5 Recent developments

  • 9.5.6 SWOT analysis

• 9.6 Boehringer Ingelheim

  • 9.6.1 Overview

  • 9.6.2 Business segments

  • 9.6.3 Product portfolio

  • 9.6.4 Financial performance

  • 9.6.5 Recent developments

  • 9.6.6 SWOT analysis

• 9.7 Impax Laboratories

  • 9.7.1 Overview

  • 9.7.2 Business segments

  • 9.7.3 Product portfolio

  • 9.7.4 Financial performance

  • 9.7.5 Recent developments

  • 9.7.6 SWOT analysis

• 9.8 Lundbeck

  • 9.8.1 Overview

  • 9.8.2 Business segments

  • 9.8.3 Product portfolio

  • 9.8.4 Financial performance

  • 9.8.5 Recent developments

  • 9.8.6 SWOT analysis

• 9.9 UCB

  • 9.9.1 Overview

  • 9.9.2 Business segments

  • 9.9.3 Product portfolio

  • 9.9.4 Financial performance

  • 9.9.5 Recent developments

  • 9.9.6 SWOT analysis

• 9.10 Valeant Pharmaceuticals

  • 9.10.1 Overview

  • 9.10.2 Business segments

  • 9.10.3 Product portfolio

  • 9.10.4 Financial performance

  • 9.10.5 Recent developments

  • 9.10.6 SWOT analysis